
    
      This is a study involving a 12 week treatment phase. During the treatment phase subjects
      receive Flutiform® or Flixotiole® and Foradil® as individual componements. Efficacy will be
      assessed by lung function tests and asthma symptoms, sleep disturbance. Safety will be
      assessed by adverse events, vital signs, lab tests and ECGs.
    
  